Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concepts to Target MYC in Pancreatic Cancer.

Molecular cancer therapeutics - 1 Aug 2016

Wirth Matthias, Mahboobi Siavosh, Krämer Oliver H, Schneider Günter

Abstract excerpt

Current data suggest that MYC is an important signaling hub and driver in pancreatic ductal adenocarcinoma (PDAC), a tumor entity with a strikingly poor prognosis. No targeted therapies with a meaningful clinical impact were successfully developed against PDAC so far. This points to the need to establish novel concepts targeting the relevant drivers of PDAC, like KRAS or MYC. Here, we discuss recent developments...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Pancreatic Ductal
Share to Carrier Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Regulatory Networks

Share to Molecular Targeted Therapy

Share to Pancreatic Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-myc

Source

Identifiers

PMID: 27406986
DOI: 10.1158/1535-7163.MCT-16-0050

Genes

MYC
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concepts to Target MYC in Pancreatic Cancer.PMID 27406986Read ↗

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathwaySemantic proximity Read ↗

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtypeSemantic proximity Read ↗

Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2Semantic proximity Read ↗

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYCSemantic proximity Read ↗

Oncogenic KRAS signalling in pancreatic cancerSemantic proximity Read ↗

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here.Semantic proximity Read ↗

Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.